<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00177866</url>
  </required_header>
  <id_info>
    <org_study_id>0312013</org_study_id>
    <nct_id>NCT00177866</nct_id>
  </id_info>
  <brief_title>Safety of Celecoxib in Patients With Crohn's Disease</brief_title>
  <official_title>The Safety of Celecoxib (Celebrex) in Patients With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shadyside Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will select 60 people who are 18-70 years of age with Crohn's disease and
      randomly assign them to receive an 8-week trial of celecoxib and an 8-week trial of a
      placebo. There will be a 1-week interval or &quot;wash-out&quot; between trials when the participant
      does not take any study medication. The investigators will monitor the participants for 18
      weeks after they start the medication and observe their Crohn's disease activity, assessing
      for flare-ups or exacerbations in the disease and other possible side effects of celecoxib.
      Based on these observations, a determination will be made by the investigators as to the
      safety of celecoxib. If celecoxib is found to be safe, then it may provide physicians with a
      medication that they can prescribe for people who have Crohn's disease and experience chronic
      pain from arthritis and arthralgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please refer to brief summary (above).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We were unable to get additional funding to complete study.
  </why_stopped>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Crohn's Disease Activity Index (CDAI) Scores in Response to Treatment</measure>
    <time_frame>completion of all study participants</time_frame>
    <description>Change in Crohn's Disease Activity Index (CDAI) scores in response to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Scores in Response to Treatment</measure>
    <time_frame>completion of all study participants</time_frame>
    <description>No results or publication, data destroyed due to age of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>A Placebo or Celebrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Placebo or Celebrex</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex</intervention_name>
    <description>Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then Celebrex 200 mg PO BID for the remaining 8 weeks.</description>
    <arm_group_label>A Placebo or Celebrex</arm_group_label>
    <other_name>Celecoxib (brand name)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo PO BID for either the first eight weeks or the last eight weeks of the study.</description>
    <arm_group_label>B Placebo or Celebrex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Greater than 18 years of age or less than 70 years of age

          2. Confirmed diagnosis of Crohn's disease

          3. Inactive disease (CDAI scores at baseline &lt;150) or active disease (CDAI scores at
             baseline &lt;200).

        Exclusion Criteria:

          1. Pregnant, nursing mothers and women of childbearing potential who are not using
             reliable contraception (i.e.: oral contraceptive pill [OCP], intrauterine device
             [IUD], Norplant)

          2. Enrolled in any other study involving non-steroidal anti-inflammatory drug (NSAID)
             medications

          3. NSAID use at time of study

          4. Baseline moderate to severe Crohn's disease activity (CDAI &gt; 200)

          5. Current treatment of less than 6 months with mercaptopurine (6 MP) or immuran.

          6. Treatment with current Crohn's medication for a period of less than 3 months

          7. Surgery for Crohn's disease (within 1 month)

          8. Known sensitivity to celecoxib, NSAIDs, or sulfonamides

          9. History of gastritis, gastrointestinal bleeding, or peptic ulcer disease

         10. Advanced kidney disease

         11. Severe hepatic impairment

         12. Subjects currently taking angiotensin-converting enzyme (ACE) inhibitors, furosemide,
             fluconazole, lithium, corticosteroids, and warfarin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George L Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>June 15, 2016</results_first_submitted>
  <results_first_submitted_qc>June 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2016</results_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>No results or publication, data destroyed due to age of study. Enrollment number retrieved from old IRB database and not from study records and cannot be verified.</recruitment_details>
      <pre_assignment_details>No results or publication, data destroyed due to age of study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Celebrex Followed by Placebo</title>
          <description>either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
Celebrex: Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then placebo PO BID for the remaining 8 weeks -</description>
        </group>
        <group group_id="P2">
          <title>Placebo Followed by Celebrex</title>
          <description>Placebo PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then Celebrex 200 mg PO BID for the remaining 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No results or publication, data destroyed due to age of study.</participants>
                <participants group_id="P2" count="0">No results or publication, data destroyed due to age of study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">No results or publication, data destroyed due to age of study.</participants>
                <participants group_id="P2" count="0">No results or publication, data destroyed due to age of study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No results or publication, data destroyed due to age of study.</population>
      <group_list>
        <group group_id="B1">
          <title>Celebrex Followed by Placebo</title>
          <description>either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
Celebrex: Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then placebo PO BID for the remaining 8 weeks -</description>
        </group>
        <group group_id="B2">
          <title>Placebo Followed by Celebrex</title>
          <description>Placebo PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then Celebrex 200 mg PO BID for the remaining 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Crohn's Disease Activity Index (CDAI) Scores in Response to Treatment</title>
        <description>Change in Crohn's Disease Activity Index (CDAI) scores in response to treatment</description>
        <time_frame>completion of all study participants</time_frame>
        <population>No results or publication, data destroyed due to age of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Celebrex Followed by Placebo</title>
            <description>either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
Celebrex: Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then placebo PO BID for the remaining 8 weeks -</description>
          </group>
          <group group_id="O2">
            <title>Placebo Followed by Celebrex</title>
            <description>Placebo PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then Celebrex 200 mg PO BID for the remaining 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Crohn's Disease Activity Index (CDAI) Scores in Response to Treatment</title>
          <description>Change in Crohn's Disease Activity Index (CDAI) scores in response to treatment</description>
          <population>No results or publication, data destroyed due to age of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Scores in Response to Treatment</title>
        <description>No results or publication, data destroyed due to age of study.</description>
        <time_frame>completion of all study participants</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celebrex Followed by Placebo</title>
            <description>either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
Celebrex: Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then placebo PO BID for the remaining 8 weeks -</description>
          </group>
          <group group_id="O2">
            <title>Placebo Followed by Celebrex</title>
            <description>Placebo PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then Celebrex 200 mg PO BID for the remaining 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Scores in Response to Treatment</title>
          <description>No results or publication, data destroyed due to age of study.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No results or publication, data destroyed due to age of study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Celebrex Followed by Placebo</title>
          <description>either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
Celebrex: Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then placebo PO BID for the remaining 8 weeks -</description>
        </group>
        <group group_id="E2">
          <title>Placebo Followed by Celebrex</title>
          <description>Placebo PO BID for the first 8 weeks, followed by a 1 week &quot;washout period&quot; then Celebrex 200 mg PO BID for the remaining 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Arnold, MD</name_or_title>
      <organization>University of Pittseburgh</organization>
      <phone>412 621-2334</phone>
      <email>Arnoldgl@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

